The GLP is committed to full transparency. Download and review our Annual Report.

Longevity science: Pioneer biotech startup wants to slow aging at ‘the cellular level’

| | April 18, 2019

What sets [Harvard geneticist David] Sinclair apart from many of his colleagues…is his willingness to test his work on himself.

“I am not going to let anyone try technology until I’ve tried it first,” Sinclair has said. Beyond eating healthily and practicing intermittent fasting, he takes daily anti-aging supplements like 0.5 grams of resveratrol mixed into homemade yogurt in the morning and metformin—a prescription drug for diabetes that also is believed to have aging-related benefits—each night.

“Thirty years ago when I started talking about this, I was considered crazy for even working in this area of biology,” Sinclair says. “It was really considered a backwater science.”

Related article:  Scavenger hunt for new antibiotics sends researchers to strange places

Today the field of longevity science—while still a playground for transhumanists and biohackers—includes some of the world’s most renowned researchers. Tech billionaires are supporting biotech companies researching the secrets of aging, like the Google-backed Calico and Jeff Bezos-backed Unity Biotechnology. Research into expanding the human lifespan is no longer automatically dismissed as charlatanry—with a few exceptions—and it is most definitely big business: The global anti-aging market was worth $42.5 billion in 2018 and is estimated to reach $55 billion by 2023. And David Sinclair is at the forefront of the movement.

Read full, original post:  Inside the Biotech Startup That Wants to Extend Your Life

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend